Context: Although mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on monotherapy in advanced disease are still scarce.
A drenocortical carcinoma (ACC) is a rare and aggressive disease with dismal prognosis and limited therapeutic options in advanced tumor stages (1, 2) . Mitotane is the only drug approved for treatment of ACC and has been in clinical use both in an adjuvant and palliative setting for many years (3) (4) (5) . However, data on the benefit of mitotane treatment are limited.
Although the approval of mitotane in most countries is restricted to ACC not amenable to complete resection, data on mitotane monotherapy in advanced ACC are scarce (2) . In fact, only 11 series with .10 patients have reported a total number of 395 patients treated with mitotane monotherapy in advanced disease. Of these studies [three prospective (6) (7) (8) , eight retrospective (3, (9) (10) (11) (12) (13) (14) (15) ] the largest series included just 67 patients in a retrospective evaluation. The overall response rate reported is only~25%. Therefore, response prediction factors would help clinicians choose the right treatment for each patient. Furthermore, the relevance of these studies for contemporary medicine is likely to be limited because most studies were performed in or even before the 1990s. Accordingly, in the majority of studies tumor response assessment was heterogeneous, and criteria are mostly not comparable with Response Evaluation Criteria in Solid Tumors (RECIST), which are now the standard of care and major endpoint in cancer trials. Of note, according to the labeling of mitotane in several countries (e.g., in the European Union) the effects of mitotane in nonfunctioning tumors has not been established. However, data supporting or disproving this statement are lacking. Although interest in mitotane as a sole firstline therapy in advanced ACC has increased recently, the lack of convincing data on monotherapy has unsettled clinicians. One reason for this "revival" of mitotane monotherapy comes indirectly from the First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment. The results of this trial suggested that the most effective therapy, the combination of etoposide, doxorubicin, cisplatin, and mitotane, is as effective as second-line therapy as it is as first-line therapy (16) . Therefore, it seems justified to test other drugs (e.g., mitotane) first.
Despite efforts by several groups, the mechanisms of action of mitotane have not been clarified. Although we recently demonstrated that mitotane induces endoplasmic reticulum stress specifically in adrenocortical carcinoma cell lines and identified inhibition of sterol O-acyltransferase 1 as a key molecular event (17) , other mechanisms are likely to be relevant and may overlap, given the high mitotane concentrations needed for efficacy. In addition, pharmacokinetic properties including basic aspects such as intestinal resorption and metabolic transformation have been only partially elucidated.
Several small studies have suggested the importance of drug monitoring in the use of mitotane. First, in 1984 van Slooten et al. (14) measured mitotane blood levels in 34 patients and found a relationship to the response rate. This concept was then confirmed in a larger retrospective series (n = 58) (11) and a small prospective study (n = 13) (8) . Since that time most authors have recommended aiming at plasma mitotane levels between 14 and 20 mg/L to increase the response rate and limit toxicity (1, 2) .
In the current large cohort study we analyzed 127 patients with advanced ACC treated at three German centers with the aim of providing efficacy data on mitotane monotherapy based on contemporary imaging methods and identifying predictive factors for treatment response to mitotane.
Subjects and Methods

Study population
Patients and clinical and histological parameters [sex; age at diagnosis; tumor size; evidence of hormone excess; tumor stage according to the European Network for the Study of Adrenal Tumors classification (18) ; date of documented unresectability; Weiss score; Ki67 index; presence, site, size, and number of tumor lesions; mitotane plasma concentration; and follow-up information) were retrieved from the German ACC Registry and the European Network for the Study of Adrenal Tumors Registry (www.ensat.org/registry). Both registries have been approved by the ethics committee of the University of Würzburg (approval numbers 86/03 and 88/11). The study is part of the German Adrenocortical Carcinoma Study group. Written informed consent was obtained from all patients. We included patients from three German centers (Würzburg, Berlin, and Munich) who fulfilled the following eligibility criteria: age $18 years, histologically confirmed ACC, advanced (i.e., not completely resectable) disease at initial diagnosis or during the course of the disease, mitotane monotherapy for $30 days, and cross-sectional imaging (abdominal and thoracic computed tomography scans, magnetic resonance imaging, or fluorodeoxyglucose positron emission tomography/computed tomography) before the start of mitotane therapy (#30 days) and regularly during mitotane treatment (at least every 4 months in the first year; median 93 days). To ensure the use of contemporary imaging methods and sufficient follow-up, inclusion was restricted to patients with a start of mitotane treatment between 01 January 1997 and 31 December 2016. Exclusion criteria were incomplete information on primary diagnosis or follow-up, concomitant therapies such as radiotherapy or cytotoxic chemotherapy, and previous therapy with mitotane. 
Mitotane dosage and drug monitoring
Response assessment
Treatment response was recorded according to routine radiologic assessment and qualified as complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD), in analogy to the RECIST 1.1 (22) . In uncertain cases (n = 12), we applied RECIST 1.1 via a blinded review of all images by a radiologist (W.S.).
Statistical analysis
Progression-free survival (PFS) was defined as the interval between the start of mitotane therapy and first documentation of PD during follow-up or censored at last follow-up. Overall survival (OS) was calculated as the time between the start of mitotane therapy and death, with censoring at last follow-up otherwise. PFS and OS were evaluated by the Kaplan-Meier method. We defined meaningful clinical benefit as disease control of .180 days, because in a recent placebo-controlled trial none of the patients without active treatment experienced disease stabilization for .150 days (23) . The following potential prognostic and predictive factors were defined before the analysis: age (dichotomized at the median), sex, endocrine activity, Ki67 index of the primary tumor, tumor burden, pattern of affected organs at the start of mitotane therapy, peak mitotane blood concentration during monotherapy or within the first 3 months of treatment, and timing of mitotane initiation. In this context patients were classified according to whether mitotane treatment was initiated for advanced disease at the time of initial diagnosis or at recurrence during follow-up. In the latter case (treatment of recurrent advanced disease) we differentiated patients according to the time between primary diagnosis and start of mitotane (,360 days, 360 to 999 days, or $1000 days). All factors were investigated by univariate analysis via Cox regression. In case of P , 0.1 in univariate analysis, multivariate analyses were performed. Tumor burden was assessed in the multivariate analysis only as the sum of tumoral lesions. The association between variables and PFS or OS was expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). Statistical significance was set at P , 0.05. To Table 1 .
Best objective response, PFS, and OS Best response was CR in three patients (2.4%), PR in 23 (18.1%), and SD in 32 patients (25.2%). Of the patients with SD, disease was controlled in 23 of them for $180 days. A total of 69 patients (54.3%) had PD at the time of first tumor evaluation. PFS was 4.1 months (range 1 to 73 months), and OS was 18.5 months (1.3 to 220 months) after initiation of mitotane (Fig. 1) . Overall, 50 patients (40.9%) experienced clinical benefit (disease control .180 days), including 28 (22.0%) with a long-term benefit of .12 months.
Predictive factors of PFS and OS
To identify possible predictive factors, univariate and multivariate analyses (adjusted by age, sex, tumor burden, and timing of mitotane initiation) were performed. Results are given in Table 2 and Fig. 2 . In short, univariate analyses showed better prognosis regarding PFS and OS for patients with Ki67 index ,10%, mitotane initiation at delayed advanced recurrence ($360 days after initial diagnosis), and low tumor burden, represented by ,10 tumoral lesions. Multivariate analyses indicated a better outcome only for low tumor burden (PFS HR 0.51, P = 0.002; 95% CI, 0.33 to 0.79; OS HR 0.59, P = 0.0017, 95% CI, 0.39 to 0.91) and timing of mitotane initiation at delayed advanced recurrence (PFS HR 0.35, P , 0.001; 95% CI, 0.23 to 0.55; OS HR 0.34, P , 0.001; 95% CI, 0.22 to 0.52). For detailed analysis including subgroups, see Table 2 .
Influence of mitotane drug levels on efficacy
Patients who reached mitotane blood levels $14 mg/L had superior PFS and OS as compared with patients in whom this blood concentration was not achieved (Table 3) . Because the association with response might be confounded by the long time interval needed to reach an effective plasma concentration, we performed a subgroup analysis in which only mitotane levels in the first 3 months were considered. Here, the effect was statistically not significant. Remarkably, the 15 patients who reached a level .20 mg/L within these first 3 months had a median PFS of 277 days (Table 3 ). The objective response rate in patients with mitotane levels $14 mg/L was also significantly higher compared with ,14 mg/L Only possible prognostic factors that showed at least a trend (P # 0.10) in univariate analysis were further investigated by multivariate analysis (adjusted by age, sex, tumor burden, and timing of mitotane initiation). Subgroups with ,127 patients in total were analyzed separately (adjusted by age, sex, tumor burden, and timing of mitotane initiation).
(31.9% vs 11.1%; P = 0.041). However, there were two patients with partial and one patient with CR whose peak levels were never .13 mg/L, including one patient with PR and a maximum documented level ,10 mg/L.
Response rates in different subgroups
In the next step we checked response rates to mitotane monotherapy in subgroups defined by potential predictive factors suggested by the current study or previous studies (9, (24) (25) (26) . We found objective response rates (PR, CR) were highest (30%) in patients with both low tumor burden and mitotane initiation at delayed advanced recurrence ($360 days after initial diagnosis) ( Table 4 ). In contrast no objective response was seen in patients with both high tumor burden and mitotane initiation at initial diagnosis or early recurrence (,360 days after primary diagnosis). Furthermore, in this subgroup only 6.3% experienced a clinical benefit (.180 days), whereas such a benefit was present in more than 67% of patients in the complementary group (Table 4) . Additionally, in 54% patients with low Ki67 index (#10%) long-term disease control was achieved in comparison with only 24% with Ki67 .20%.
Discussion
Although mitotane is the only approved drug for the treatment of patients with ACC, reliable data on mitotane monotherapy are surprisingly scarce. Here, we present the https://academic.oup.com/jcemlargest study analyzing the effects of mitotane monotherapy in 127 patients with advanced disease. We demonstrate that mitotane leads to an objective response rate of 21% (including three patients with CR). Furthermore, an additional 25% of patients experienced SD, translating to a median PFS of 4.1 months and OS of 18.5 months. Although a median PFS of 4 months is not impressive, it compares favorably with those of other drugs investigated for ACC [23, 27-30; for review see (2)]. However, without a doubt these trials are not readily comparable (e.g., because of different imaging intervals). Nevertheless, this study clearly shows that mitotane can induce objective response in a percentage of patients and can control advanced disease in a subgroup for a long time.
A key result of our study is the observation that patients who started mitotane after late recurrence did much better than those who had advanced disease at the time of initial diagnosis. Patients with late recurrence have a better prognosis because these tumors are usually less aggressive (31) . However, this fact does not necessarily explain the higher objective response rate in this cohort (Table 4) . High tumor burden, described in terms of maximal tumor diameter or number of tumoral lesions or organs, is associated with poor prognosis in literature (2, 32) . Here, we confirm that tumor load is an important prognostic factor. Of note, our data seem to suggest that low tumor burden is also a predictive factor for response to mitotane treatment, because 71% of patients with ,10 tumoral lesions experienced disease control for .6 months, whereas this was the case in only 18% of patients with higher tumor load.
Patients with a Ki67 index #10% had a longer OS than patients with a Ki67 index $20%. These results are in line with previous studies that described Ki67 as an important prognostic marker in ACC, which appears to have less discriminative value in advanced disease (33) . Tumors with low Ki67 seem to respond slightly better than tumors with high proliferative activity. However, Ki67 staining of the primary tumor is most probably not the ideal way to judge the clinical behavior of a tumor that recurred in almost half of the patients .1 year after the initial surgery.
Mitotane therapy and mitotane blood levels have been shown to be correlated with objective response rate and Only possible prognostic factors that showed at least a trend (P # 0.10) in univariate analysis were further investigated by multivariate analysis (adjusted by age, sex, tumor burden, and timing of mitotane initiation).
PFS or OS in patients with advanced or recurrent ACC (8, 9, 11, 34) . In our study a trend toward longer PFS with higher peak mitotane blood levels during therapy could be seen in multivariate analysis. Regarding OS, results show a significant correlation between higher mitotane levels and longer survival. However, the so-called immortal time bias may partially explain this finding, meaning that higher mitotane levels correlate with treatment duration, and this certainly comes with longer survival. If we used only the mitotane measurements in the first 3 months of therapy, there was no significant correlation with PFS or OS. However, the number of patients in this subanalysis might have been too small to allow strong conclusions. Furthermore, the initial dosage of mitotane might influence the time interval to reach relevant plasma levels, although an earlier analysis suggested no significant difference between two starting regimens in the first 12 weeks (21) . Therefore, additional studies on mitotane blood levels in the first weeks after initiation are warranted to investigate its value as predictive marker for outcome. Interestingly, we have seen objective response in three patients who never reached the "therapeutic concentration" of 14 mg/L. Thus, a level $14 mg/L seems desirable, but lower levels do not preclude clinical benefit. Several studies have shown worse prognosis for cortisol-producing tumors (26, 35, 36) . In our cohort we could not show any difference in PFS and OS between patients with and without cortisol-producing ACC. This limitation might reflect the small number of patients (n = 80) for whom we had sufficient information about the endocrine function of their ACC. Furthermore, only 34 patients had overt Cushing syndrome, and only 5 had to be treated with steroidogenesis inhibitors, suggesting that only a minority of the cohort had severe hypercortisolism not controlled by mitotane. However, our study provides important additional information for the official labeling of mitotane in several countries (e.g., in the European Union), where it is mentioned that the effects of mitotane in nonfunctioning tumors have not been established. Our study clearly suggests that mitotane is effective independent of the endocrine activity of the tumor. Therefore, as is already clinical practice in most expert centers, we recommend administering mitotane in both functioning and nonfunctioning tumors.
Our study has obvious limitations. Its retrospective design and the lack of a control group hinder a proper separation of the effects of mitotane from other known and unknown prognostic factors in ACC. However, a placebo-controlled trial might be unethical because it is well known that almost all ACCs progress rapidly if left untreated, as prospectively demonstrated in the placebocontrolled phase III trial with linsitinib (23) . Furthermore, patients in our cohort probably are not representative of the entire group of patients with advanced ACC because patients with aggressive tumors might be selected for the immediate start of adjunctive cytotoxic chemotherapy. Another weakness is the small number of cases, which precluded detailed subgroup analyses. On the other hand, 127 patients can be considered a large number in 
Conclusions
This study on mitotane monotherapy demonstrated that this drug is able to achieve clinical benefit for patients with advanced ACC. Although the objective response rate was slightly lower than reported previously, the fact that a fifth of the cohort had clear tumor shrinkage proves the efficacy of the drug. This finding is further substantiated by the 20% of patients who experienced longterm disease control for .1 year. Our study suggests that patients with less aggressive tumors (e.g., low-grade tumors with low tumor burden and a long interval between initial diagnosis and the need to start systemic therapy) might be especially good candidates for mitotane monotherapy. In contrast, patients with advanced disease at primary diagnosis and high tumor loads probably benefit more from early administration of cytotoxic drugs.
